New drug duo targets Hard-to-Treat breast cancer

NCT ID NCT07597629

Recruiting now Disease control Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two drugs together for people with advanced breast cancer that cannot be removed by surgery. SYS6023 targets a protein called HER3 on cancer cells, while KN026 targets HER2. The goal is to see if the combination is safe and shrinks tumors. About 36 adults with confirmed HER3-positive breast cancer will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SYS6023 (a drug that targets HER3 on cancer cells) and KN026 (a drug that targets HER2 on cancer cells)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced breast cancer that has not responded to other therapies.
What could go wrong: This is an early Phase II trial with only 36 participants, so results may not apply to everyone. The drugs may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER

Contacts and locations

Locations

Affiliated Tumor Hospital of Harbin
RECRUITING

Harbin, Heilonjiang, 150000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.